AR046832A1 - Ensayos de rastreo y metodos de tratamiento de tumores - Google Patents

Ensayos de rastreo y metodos de tratamiento de tumores

Info

Publication number
AR046832A1
AR046832A1 ARP040104077A ARP040104077A AR046832A1 AR 046832 A1 AR046832 A1 AR 046832A1 AR P040104077 A ARP040104077 A AR P040104077A AR P040104077 A ARP040104077 A AR P040104077A AR 046832 A1 AR046832 A1 AR 046832A1
Authority
AR
Argentina
Prior art keywords
soft tissue
growth
primary tumor
treatment methods
tumor treatment
Prior art date
Application number
ARP040104077A
Other languages
English (en)
Spanish (es)
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AR046832A1 publication Critical patent/AR046832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/495—Transforming growth factor [TGF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
ARP040104077A 2003-11-13 2004-11-05 Ensayos de rastreo y metodos de tratamiento de tumores AR046832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52039803P 2003-11-13 2003-11-13
US55795104P 2004-03-31 2004-03-31

Publications (1)

Publication Number Publication Date
AR046832A1 true AR046832A1 (es) 2005-12-28

Family

ID=34623132

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104077A AR046832A1 (es) 2003-11-13 2004-11-05 Ensayos de rastreo y metodos de tratamiento de tumores

Country Status (13)

Country Link
US (1) US20060015952A1 (https=)
EP (1) EP1682890A2 (https=)
JP (1) JP2007515949A (https=)
KR (1) KR20060127409A (https=)
AR (1) AR046832A1 (https=)
AU (1) AU2004292180A1 (https=)
BR (1) BRPI0416305A (https=)
CA (1) CA2542215A1 (https=)
IL (1) IL174916A0 (https=)
NO (1) NO20062715L (https=)
RU (1) RU2006120483A (https=)
TW (1) TW200526957A (https=)
WO (1) WO2005050200A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7649013B2 (en) * 2003-11-26 2010-01-19 Arqule, Inc. Methods of protecting against radiation injury
EP1740615B1 (en) * 2004-03-31 2014-11-05 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7412026B2 (en) * 2004-07-02 2008-08-12 The Board Of Regents Of The University Of Oklahoma Phase-contrast x-ray imaging systems and methods
US7853626B2 (en) 2006-09-29 2010-12-14 The Invention Science Fund I, Llc Computational systems for biomedical data
US10546652B2 (en) * 2006-09-29 2020-01-28 Gearbox Llc Computational systems for biomedical data
US20080082583A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080082359A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of State Of Delaware Computational systems for biomedical data
US20080082367A1 (en) * 2006-09-29 2008-04-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US10095836B2 (en) * 2006-09-29 2018-10-09 Gearbox Llc Computational systems for biomedical data
US10503872B2 (en) 2006-09-29 2019-12-10 Gearbox Llc Computational systems for biomedical data
US10068303B2 (en) 2006-09-29 2018-09-04 Gearbox Llc Computational systems for biomedical data
US8122073B2 (en) 2006-09-29 2012-02-21 The Invention Science Fund I Computational systems for biomedical data
US20080091730A1 (en) * 2006-09-29 2008-04-17 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US20080109484A1 (en) * 2006-09-29 2008-05-08 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems for biomedical data
US8491890B2 (en) * 2008-07-09 2013-07-23 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
BRPI0923155A2 (pt) 2008-12-05 2018-10-23 Abraxis Bioscience Llc scfcs de ligação a sparc
WO2010124276A2 (en) 2009-04-24 2010-10-28 Vanderbilt Universtiy Anti-tgf-beta induction of bone cell function and bone growth
US8476246B2 (en) * 2009-07-30 2013-07-02 Antisense Pharma Gmbh Combination of a chemotherapeutic agent and an inhibitor of the TGF-beta system
US20120208209A1 (en) * 2009-10-30 2012-08-16 Marina Ichetovkin Pcsk9 immunoassay
SI2835053T1 (sl) 2010-03-12 2016-09-30 Genzyme Corporation Kombinirana terapija za zdravljenje raka dojke
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
US12156912B2 (en) 2012-05-18 2024-12-03 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting diseases of the central nervous system
KR101479543B1 (ko) * 2013-03-15 2015-01-07 서강대학교산학협력단 Ｔｆｇ－ｔｅｃ 융합 컨스트럭트를 이용한 종양 질환의 예방 또는 치료용 물질의 스크리닝 방법 및 이의 용도
US10550196B2 (en) 2014-04-27 2020-02-04 Famewave Ltd. Humanized antibodies against CEACAM1
US11427647B2 (en) 2014-04-27 2022-08-30 Famewave Ltd. Polynucleotides encoding humanized antibodies against CEACAM1
EP3234120B1 (en) 2014-12-15 2025-09-03 The Regents of the University of California Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing
FI3240805T3 (fi) 2014-12-15 2025-02-17 Univ California Cd19- ja cd20-vasteellinen bispesifinen tai-veräjän kimeerinen antigeenireseptori
AU2016331081B2 (en) 2015-10-02 2021-04-29 Wake Forest University Health Sciences Methods and apparatus for modeling cancer metastasis in vitro
PL3368571T3 (pl) * 2015-10-30 2023-05-02 The Regents Of The University Of California Polipeptydy odpowiadające na transformujący czynnik wzrostu beta i sposoby ich zastosowania
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US12038432B2 (en) 2018-02-02 2024-07-16 Wake Forest University Health Sciences Organoids related to immunotherapy and methods of preparing and using the same
CN112566936B (zh) 2018-08-21 2024-07-12 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体
WO2020124084A1 (en) * 2018-12-15 2020-06-18 The Brigham And Women's Hospital, Inc. Augmented digital microscopy for lesion analysis
CN111088227A (zh) * 2019-12-31 2020-05-01 广州航华生物医药科技有限公司 一种细胞分离培养液和t细胞分离培养的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001410A1 (en) * 1998-07-06 2000-01-13 Beth Israel Deaconess Medical Center Methods of inhibiting proliferative diseases by inhibiting tgf-beta mediated angiogenesis
WO2001057061A1 (en) * 2000-02-04 2001-08-09 California Pacific Medical Center Research Institute Novel use of ribozymes to block gene expression
US20010046502A1 (en) * 2000-02-04 2001-11-29 The Board Of Trustees Of The University Of Illinois Animal model for testing immunotherapies of spontaneous metastatic disease
CA2298737A1 (en) * 2000-02-10 2001-08-10 Manikkam Suthanthiran 2167334tgf-.beta. antagonists to inhibit tumor cell formation or progression
US6632979B2 (en) * 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
US6767541B2 (en) * 2000-03-20 2004-07-27 The Regents Of The University Of California HER-2/neu overexpression abrogates growth inhibitory pathways
US20030125251A1 (en) * 2001-06-21 2003-07-03 Wakefield Lalage M. Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta

Also Published As

Publication number Publication date
EP1682890A2 (en) 2006-07-26
AU2004292180A1 (en) 2005-06-02
WO2005050200A3 (en) 2005-12-01
JP2007515949A (ja) 2007-06-21
RU2006120483A (ru) 2007-12-20
WO2005050200A9 (en) 2005-08-18
NO20062715L (no) 2006-08-11
US20060015952A1 (en) 2006-01-19
KR20060127409A (ko) 2006-12-12
TW200526957A (en) 2005-08-16
IL174916A0 (en) 2006-08-20
AU2004292180A2 (en) 2005-06-02
WO2005050200A2 (en) 2005-06-02
CA2542215A1 (en) 2005-06-02
BRPI0416305A (pt) 2007-01-09

Similar Documents

Publication Publication Date Title
AR046832A1 (es) Ensayos de rastreo y metodos de tratamiento de tumores
CY1120496T1 (el) Μεθοδος για τη δημιουργια ενος ζωου ομοζυγου για μια γενετικη τροποποιηση
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
ATE487503T1 (de) Medizinprodukt mit fixiermitteln
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
BRPI0513896A (pt) método para a discriminação entre tecido saudável e de tumor
AR057323A1 (es) Metodo para la prediccion de la respuesta a un tratamiento
CO2022000402A2 (es) Uso de linfocitos t con receptor de antígeno quimérico e inhibidores de linfocitos citolíticos naturales para el tratamiento del cáncer
MX2019005150A (es) Inhibidores de la tirosina-cinasa de bruton.
AR066124A1 (es) Metodos para seleccionar plantas de soja resistentes a la podredumbre de la raiz de phytophthora (prr) mediante el empleo de marcadores de "polimorfismo de nucleotido individual" (snp)
MX349622B (es) Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
MX2023007587A (es) Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb).
MX2023012316A (es) Prueba a base de hisopos orales para la deteccion de estados patologicos dentarios en gatos domesticos, perros y otros mamiferos.
MX2018015710A (es) Análogos fosfolipídicos de éter para la identificación y el aislamiento de células tumorales circulantes.
ECSP088636A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos, y métodos de uso en la terapia de cáncer
CL2023003123A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
MX2019002929A (es) Biomarcadores de arn para angioedema hereditario.
AR030643A1 (es) Composiciones y metodos para la deteccion de biomarcadores relacionados con la enfermedad cardiovascular
BR112017003751A2 (pt) medida e diagnóstico de ruído em ambiente urbano
DE602006011607D1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
AR037756A1 (es) Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma.
BR112021020779A2 (pt) Métodos aperfeiçoados para o diagnóstico precoce de leiomimas uterinos e leiomimas

Legal Events

Date Code Title Description
FB Suspension of granting procedure